Integrin-mediated drug resistance in multiple myeloma

Leukemia and Lymphoma

Volumn 38, Issue 1-2, 2000, Pages 71-81

  Damiano, Jason S ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cell adhesion; Drug resistance; Integrins; Myeloma

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; INTEGRIN;

BONE MARROW; CELL ADHESION; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW;

EID: 0034009920     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009060320     Document Type: Review

References (42)

1. Clark EA, Brugge JS. (1995) Integrins and signal transduction pathways: the road taken. Science 268 (5208), 233-239.
2. Hynes RO. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1), 11-25.
3. Malik RK. (1997) Regulation of apoptosis by integrin receptors. Journal of Ped. Hem/Onc. 19, 541-545.
4. Dalton WS. (1997) Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol. 34, (4 Suppl 5), 3-8.
5. Broxterman HJ, Giaccone AG, Lankelma J. (1995) Multidrug resistance proteins and other transport-related resistance to natural product agents. Curr. Opin. Onc. 7 (6), 532-540.
6. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. (1989) Plasma cell myeloma: new biological insights and advances in therapy. Blood 73 (4): 865-879.
7. Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei E III. (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247 (4949 pt. 1). 1457-61.
8. Bradstock KF, Gottlieb DJ. (1995) Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk. Lymph. 18(1-2), 1-16.
9. Caligaris-Cappio F, Gregoretti MG, Merico F, Gorrardi D, Ghia P, Parvis G, Bergui L. (1992) Bone marrow microenvironment and the progression of multiple myeloma. Leuk. Lymph. 8 (1-2), 15-22.
10. Barker HF, Ball J, Drew M, Hamilton MS, Franklin IM. (1992) The role of adhesion molecules in multiple myeloma. Leuk. Lymph. 8 (3), 189-196.
11. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. (1992) Characterization of adhesion molecules on human myeloma cell lines. Blood 90 (9), 2306-2314.
12. St Croix B, Kerbel RS. (1997) Cell adhesion and drug resistance in cancer. Curr. Opin. Oncol. 9 (6), 549-556.
13. Lagneaux L, Delforge A, Bron D, De Bruyn C, Strykmans P. (1998) Chronic lymphocytic leukemic B cells hut not normal B cells are rescued from apoptosis by contact with normanl bone marrow stromal cells. Blood 91 (7), 2387-2396.
14. Kibler C, Schermutzki F, Waller HD, Timpl R, Muller CA, Klein G. (1998) Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes. Commun. 5, 307-23.
15. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. (1999) Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93 (5), 1658-1667.
16. Grigorieva I, Thomas X, Epstein J. (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp. Hematol. 26 (7), 597-603.
17. Zhang Z, Vuori K, Reed JC, Ruoslahti E. (1995) The alpha5 betal integrin suports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc. Natl. Acad. Sci. USA 92 (13), 6161-6165.
18. Higashimoto I, Chihara J, Kakazu T, Kawabata M, Nakajuma S, Osame M. (1996) Regulation of eosinophil cell death by adhesion to fibronectin. Int. Arch. Allergy Immunol. 111 (1), 66-69.
19. Fukai F, Mashimo M, Akiyama K, Goto T, Tanuma S-I, Katayama T. (1998) Modulation of apoptotic cell death by extracellular matrix proteins and a fibronectin-derived anti-adhesive peptide. Exp. Cell Res. 242 (1), 92-99.
20. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. (1991) Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 51 (3), 995-1002.
21. Dalton WS, Salmon SE. (1992) Drug resistance in myeloma: mechanisms and approaches to circumvention. Hematol. Oncol. Clin. North Am. 6, 383-93.
22. Wang H, Jiang Zg, Wong YW, Dalton WS, Futscher BW, Chan VT. (1997) Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem. Biophys. Res. Commun. 237 (2), 217-24.
23. Zaitseva MB, Mojcik CF, Salomon SR, Shevach EM, Golding H. (1998) Co-ligation of α4β1 integrin and TCR rescues human thymocytes from steroid-induced apoptosis. Int. Immun. 10 (10), 1551-1561.
24. Hughes PE and Pfaff M. (1998) Integrin affinity modulation. Trends Cell Biol. 8 (9), 359-364.
25. Gailit J and Ruoslahti E. (1988) Regulation of the fibronectin receptor affinity by divalent cations. J. Biol. Chem. 263 (26), 12927-12932.
26. Arroyo AG, Sanchez-Mateos P, Campanero MR, Marlin-Padura I, Dejana E. Sanchez-Madrid F. (1992) Regulation of the VLA integrin-ligand interactions through the betal subunit. J. Cell Biol. 117 (3), 659-670.
27. Altieri DC Bader R, Mannucci PM, Edginton TS. (1988) Oligospecificty of the cellular adhesion recepctor Mac-1 encompasses recognition specificity for fibrinogen. J Cell Biol. 107(5), 1893-1900.
28. Pulido R, Elices MJ, Campanero MR, Osborn L, Schiffer S, Garcia-Pardo A, Lobb R, Hemler ME, Sanchez-Madrid F. (1991) Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. J. Biol. Chem. 266 (16), 10241-10245.
29. Stewart M and Hogg N. (1996) Regulation of leukocyte integrin function: affinity vs. avidity. J. Cell Biochem. 61 (4), 554-561.
30. Stewart MP, McDowall A, Hogg N. (1998) LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain. J. Cell Biol. 140 (3), 699-707.
31. Kucik DF, Dustin ML, Miller JM, Brown EJ. (1996) Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes. J. Clin. Invest. 97 (9), 2139-2144.
32. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C. (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine 5 (6), 662-668.
33. Bozzo C, Bellomo G, Silengo L, Tarone G, Altruda F. (1997) Soluble integrin ligands and growth factors independently rescue neuroblastoma cells from apoptosis under nonadherent conditions. Exp. Cell. Res. 237 (2), 326-337.
34. De la Fuente M-T, Casanova B, Garcia-Gila M, Silva A. and Garcia-Pardo A. (1999) Fibronectin interaction with α4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 13 (2), 266-274.
35. Frisch SM, Ruoslahti E. (1997) Integrins and anoikis. Curr. Opin. Cell Biol. 9 (5), 701-706.
36. Hungerford JE, Compton MT, Matter ML, Hoffstrom BG, Otey CA. (1996) Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J. Cell Biol. 135 (5), 1383-1390.
37. Cary LA, Guan J-L. (1999) Focal adhesion kinase in integrin-mediated signaling. Front. Biosci. 4, 102-113.
38. King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS. (1997) Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol. Cell. Biol. 17 (8), 4406-4418.
39. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. (1998) Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J. Cell Biol. 143 (2), 547-60.
40. Schlaepfer DD, Hauck CR, Sieg DJ. (1999) Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 71, 435-78.
41. Rodeck U, Jost M, DuHadaway J, Kari C, Jensen PJ, Risse B. Ewert DL. (1997) Regulation of Bcl-XI expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor. Proc. Nat. Acad. Sci. USA 94 (10), 5067-5072.
42. Hazlehurst LA, Wisner L, Dalton WS. (1999) Activation of β1 integrin induces intrinsic drug resistance in the myeloma 8226 cell line: correlation with decreased proliferative index and increased p27 levels. Proc AACK 40, 324.